Estimating the economic burden of typhoid in children and adults in Blantyre, Malawi: A costing cohort study

PLoS One. 2022 Nov 23;17(11):e0277419. doi: 10.1371/journal.pone.0277419. eCollection 2022.

Abstract

Background: Typhoid causes preventable death and disease. The World Health Organization recommends Typhoid Conjugate Vaccine for endemic countries, but introduction decisions depend on cost-effectiveness. We estimated household and healthcare economic burdens of typhoid in Blantyre, Malawi.

Methods: In a prospective cohort of culture-confirmed typhoid cases at two primary- and a referral-level health facility, we collected direct medical, non-medical costs (2020 U.S. dollars) to healthcare provider, plus indirect costs to households.

Results: From July 2019-March 2020, of 109 cases, 63 (58%) were <15 years old, 44 (40%) were inpatients. Mean hospitalization length was 7.7 days (SD 4.1). For inpatients, mean total household and provider costs were $93.85 (95%CI: 68.87-118.84) and $296.52 (95%CI: 225.79-367.25), respectively. For outpatients, these costs were $19.05 (95%CI: 4.38-33.71) and $39.65 (95%CI: 33.93-45.39), respectively. Household costs were due mainly to direct non-medical and indirect costs, medical care was free. Catastrophic illness cost, defined as cost >40% of non-food monthly household expenditure, occurred in 48 (44%) households.

Conclusions: Typhoid can be economically catastrophic for families, despite accessible free medical care. Typhoid is costly for government healthcare provision. These data make an economic case for TCV introduction in Malawi and the region and will be used to derive vaccine cost-effectiveness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Cohort Studies
  • Cost of Illness
  • Financial Stress
  • Humans
  • Malawi / epidemiology
  • Prospective Studies
  • Typhoid Fever* / epidemiology
  • Typhoid Fever* / prevention & control
  • Typhoid-Paratyphoid Vaccines*

Substances

  • Typhoid-Paratyphoid Vaccines

Grants and funding

This work was supported by a grant from PATH, as part of the Typhoid Vaccine Acceleration Consortium (TyVAC). TyVAC is a partnership between the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, the Oxford Vaccine Group at the University of Oxford, and PATH, an international non-profit. TyVAC is funded by the Bill & Melinda Gates Foundation (OPP1151153). There was no additional external funding received for this study.